journal
MENU ▼
Read by QxMD icon Read
search

Antiviral Therapy

journal
https://www.readbyqxmd.com/read/28091393/viral-blips-were-infrequent-in-treatment-naive-adults-treated-with-rilpivirine-emtricitabine-tenofovir-df-or-efavirenz-emtricitabine-tenofovir-df-through-96-weeks
#1
Danielle P Porter, Rima Kulkarni, Will Garner, Michael D Miller, Kirsten L White
BACKGROUND: The clinical impact of transient episodes of HIV viremia (viral blips) on virologic failure and resistance development is not fully understood. Here we investigated the blip frequency and virologic outcomes of HIV-1-infected subjects experiencing viral blips among treatment-naïve subjects initiating therapy on rilpivirine (RPV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) or efavirenz (EFV)/FTC/TDF through 96 weeks of treatment. METHODS: Subjects treated with at least one dose of study drug and with at least one post-baseline HIV-1 RNA value were included in this analysis...
January 16, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28091392/the-impact-of-viral-load-and-time-to-onset-of-cytomegalovirus-replication-on-long-term-graft-survival-after-kidney-transplantation
#2
Tomas Reischig, Martin Kacer, Petra Hruba, Pavel Jindra, Ondrej Hes, Daniel Lysak, Mirko Bouda, Ondrej Viklicky
BACKGROUND: Asymptomatic cytomegalovirus (CMV) infection is associated with graft dysfunction and failure. However, no study assessed CMV viral load in terms of the risk for graft failure. METHODS: In prospective cohort of kidney transplant recipients, we assessed the impact of CMV DNAemia on the overall graft survival and the incidence of moderate-to-severe interstitial fibrosis and tubular atrophy (IF/TA) in protocol biopsy at 36 months. CMV DNAemia was stratified by viral load in whole blood...
January 16, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28085003/prevalence-of-sofosbuvir-resistance-associated-variants-in-brazilian-and-worldwide-ns5b-sequences-of-genotype-1-hcv
#3
Allan Peres-da-Silva, Carlos Eduardo Brandão-Mello, Elisabeth Lampe
BACKGROUND: The prevalence of natural polymorphisms associated with resistance to NS5B NI sofosbuvir is distinct in different geographical regions. In Brazil, direct acting anti-HCV therapy has recently changed by the introduction of IFN-free regimens with sofosbuvir and the presence of resistant variants on clinical outcomes remains unknown. The aim of this study was to assess the natural polymorphisms associated with resistance to the NS5B NI sofosbuvir in Brazilian HCV-1 isolates and to compare it with that from other geographic regions...
January 13, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28085002/hcv-intergenotype-2k-1b-recombinant-detected-in-a-daa-treated-patient-in-italy
#4
Stefania Paolucci, Marta Premoli, Serena Ludovisi, Mario U Mondelli, Fausto Baldanti
Direct acting antiviral (DAA) combinations are potent and effective drugs currently recommended for treatment of chronic HCV infection. Difficult to treat genotypes are the most important predictors of treatment failure. We report a case of DAA treatment failure in a HCV infected patient carrying a recombinant genotype 2k/1b. This strain first isolated from a Russian patient in 2002, has now been observed for the first time in Italy.
January 13, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28076335/infrequent-development-of-drug-resistance-in-hiv-1-infected-treatment-naive-subjects-after-96-weeks-of-treatment-with-elvitegravir-cobicistat-emtricitabine-tenofovir-alafenamide-or-elvitegravir-cobicistat-emtricitabine-tenofovir-disoproxil-fumarate
#5
Nicolas Margot, Stephanie Cox, Moupali Das, Scott McCallister, Michael D Miller, Christian Callebaut
BACKGROUND: Tenofovir alafenamide (TAF) is a novel prodrug of the nucleotide RT inhibitor (NtRTI) tenofovir (TFV) that loads lymphocytes with TFV-diphosphate more efficiently than tenofovir disoproxil fumarate (TDF). The single-tablet regimen (STR) composed of elvitegravir/cobicistat/emtricitabine/TAF (E/C/F/TAF) has demonstrated non-inferiority to the STR of E/C/F/TDF in clinical studies, with high proportions of subjects achieving HIV-1 RNA <50 copies/mL at week 48, and maintained through week 96...
January 11, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28067632/hcv-genotype-1-subtypes-and-resistance-associated-substitutions-in-drug-naive-and-in-direct-acting-antiviral-treatment-failure-patients
#6
Yael Gozlan, Ziv Ben-Ari, Roy Moscona, Rachel Shirazi, Avia Rakovsky, Arij Kabat, Ella Veizman, Tania Berdichevski, Peretz Weiss, Oranit Cohen-Ezra, Yoav Lurie, Inna Gafanovich, Marius Braun, Michal Cohen-Naftaly, Amir Shlomai, Oren Shibolet, Ehud Zigmond, Eli Zuckerman, Michal Carmiel-Haggai, Assy Nimer, Rawi Hazzan, Yaakov Maor, Yona Kitay-Cohen, Yonat Shemer, Zipi Kra-Oz, Lisita Schreiber, Ofer Peleg, Ella Mendelson, Orna Mor
BACKGROUND: Direct-acting antiviral (DAA) treatment regimens and response rates of patients with hepatitis C virus (HCV) genotype 1 (GT1) are currently considered subtype-dependent. Identification of clinically relevant resistance-associated substitutions (RASs) in the NS3 and NS5A proteins at baseline and in DAA failures, may also impact clinical decisions. METHODS: In a multicenter cohort study (n=308), NS3 or NS5B sequencing (n=248) was used to discriminate between GT1 subtypes...
January 9, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28054933/association-of-hiv-infection-with-biomarkers-of-kidney-injury-and-fibrosis-in-the-multicenter-aids-cohort-study
#7
Vasantha Jotwani, Rebecca Scherzer, Michelle M Estrella, Lisa P Jacobson, Mallory D Witt, Frank Palella, Ken Ho, Michael Bennett, Chirag R Parikh, Joachim H Ix, Michael Shlipak
BACKGROUND: Chronic kidney disease (CKD) is common among HIV-infected individuals, but serum creatinine is insensitive for detecting kidney damage at early stages. We hypothesized that HIV infection would be associated with elevations in subclinical markers of kidney injury and fibrosis in a contemporary cohort of men. METHODS: In this cross-sectional study, we measured urine levels of interleukin-18 (IL-18), kidney injury molecule-1 (KIM-1), pro-collagen type III N-terminal pro-peptide (PIIINP), and albumin-creatinine ratio (ACR) in 813 HIV-infected and 331 uninfected men enrolled in the Multicenter AIDS Cohort Study...
January 5, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28054932/hiv-infection-rather-than-concurrent-opportunistic-infections-drives-most-systemic-procoagulant-vascular-and-damage-responses-a-prospective-cohort-study-in-central-africa
#8
Saskia Janssen, Michaela Am Huson, Kara K Osbak, Elie-Gide Rossatanga, Abraham Alabi, René Lutter, Martin P Grobusch, Tom van der Poll
BACKGROUND: HIV infection is accompanied by various systemic host responses, including activation of coagulation and the vascular endothelium. We sought to determine the impact of opportunistic co-infections in a Central-African setting. METHODS: This prospective study included 98 HIV-infected individuals in Gabon initiating combination antiretroviral therapy (cART) and followed them up for 6 months. Patients were stratified according to the presence of active tuberculosis (TB; n=19), mucocutaneous opportunistic infection (n=9), or no opportunistic infection (n=70)...
January 5, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28054931/life-expectancy-after-initiation-of-combination-antiretroviral-therapy-in-thailand
#9
Sirinya Teeraananchai, Suchada Chaivooth, Stephen J Kerr, Sorakij Bhakeecheep, Anchalee Avihingsanon, Achara Teeraratkul, Petchsri Sirinirund, Matthew G Law, Kiat Ruxrungtham
BACKGROUND: Access to combination antiretroviral therapy (cART) has decreased mortality in HIV positive people. We aimed to estimate the expected additional years of life in HIV-positive Thai people after starting cART through the National AIDS Program (NAP), administered by the Thai National Health Security Office (NHSO). METHODS: The NHSO database collects characteristics of all Thai HIV-infected patients through the National AIDS Program, including linkage with the National Death Registry for vital status...
January 5, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28051809/pregnancy-related-changes-of-antiretroviral-pharmacokinetics-an-argument-for-tdm
#10
Francesco R Simonetti, Dario Cattaneo, Nadia Zanchetta, Vania Giacomet, Valeria Micheli, Nadia Ciminera, Cristina Gervasoni
Here we describe a case of an HIV-infected young woman with extensive drug-resistant virus, who was successfully switched from a raltegravir-based regimen to a dolutegravir-based intensified antiretroviral regimen a few days before scheduled caesarean section because of the still detectable viral load. The trough concentrations of all antiretroviral drugs before and after delivery are also described.Our case underlines both the difficult management of young women, HIV-infected at young age with very limited treatment options and the great variability in the pregnancy-related physiologic changes affecting the pharmacokinetics of antiretrovirals...
January 4, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28008868/effect-of-minor-populations-of-ns5a-and-ns5b-resistance-associated-variants-on-hcv-genotype-3-response-to-daclatasvir-plus-sofosbuvir-with-or-without-ribavirin
#11
Fiona McPhee, Dennis Hernandez, Nannan Zhou
BACKGROUND: Treatment of hepatitis C virus (HCV) genotype 3 (GT3) is a medical priority. All-oral treatment of HCV GT3 with daclatasvir (DCV) and sofosbuvir (SOF), with or without ribavirin (RBV), is recommended by several treatment guidelines. The impact of HCV minority populations at amino acid positions in NS5A and NS5B associated with drug resistance on response to DCV+SOF±RBV was assessed in SOF-naive and SOF-experienced HCV patients. METHODS: The presence of baseline NS5A or NS5B polymorphisms was assessed in 227 and 167 HCV-GT3-infected patients, respectively, from four clinical studies of DCV+SOF±RBV...
December 23, 2016: Antiviral Therapy
https://www.readbyqxmd.com/read/28008867/dolutegravir-plasma-concentrations-according-to-companion-antiretroviral-drug-unwanted-drug-interaction-or-desirable-boosting-effect
#12
Dario Cattaneo, Davide Minisci, Valeria Cozzi, Agostino Riva, Paola Meraviglia, Emilio Clementi, Massimo Galli, Cristina Gervasoni
BACKGROUND: Studies in healthy volunteers have shown that the recently approved HIV integrase inhibitor dolutegravir has limited drug-to-drug interaction profile. Here we carried out a pharmacokinetic survey in HIV-infected patients given dolutegravir as part of their antiretroviral therapy. METHODS: Dolutegravir plasma trough concentrations were measured in 78 HIV infected patients given the drug in combination with a protease inhibitor, a non nucleoside reverse transcriptase inhibitor or abacavir/lamivudine...
December 23, 2016: Antiviral Therapy
https://www.readbyqxmd.com/read/28008866/antiviral-potential-and-mode-of-action-of-indigofera-heterantha-against-hsv-2-by-targeting-the-early-stages-of-infection
#13
Natasha Kapoor Kaushik, Rupa Guha, Becky M Thomas
BACKGROUND: The development of antivirals against herpes simplex virus 2 (HSV-2) has a major public health importance because of the wide spectrum of associated clinical disease in both immunocompetent and immunocompromised populations. Even with the extensive use of acyclovir, issues such as emergence of drug resistant strains, poor oral bioavailability, and low effectiveness in recurrent infections have highlighted the requirement for alternate therapies. Plants, which are rich in metabolites and active against viruses, are being explored as one such source...
December 23, 2016: Antiviral Therapy
https://www.readbyqxmd.com/read/27977411/dolutegravir-monotherapy-when-should-clinical-practice-be-clinical-research
#14
Joel Gallant, Jeremy Sugarman
No abstract text is available yet for this article.
December 15, 2016: Antiviral Therapy
https://www.readbyqxmd.com/read/27834772/early-neuropsychological-adverse-events-after-switching-from-pi-r-to-dolutegravir-could-be-related-to-hyperthyroidism-in-patients-under-levothyroxine
#15
Jean-Luc Berger, Yohan Nguyen, Delphine Lebrun, Caroline Migault, Maxime Hentzien, Hélène Marty, Firouzé Bani-Sadr
No abstract text is available yet for this article.
December 11, 2016: Antiviral Therapy
https://www.readbyqxmd.com/read/27934775/real-world-effectiveness-and-predictors-of-sustained-virological-response-with-all-oral-therapy-in-21-242-hepatitis-c-genotype-1-patients
#16
Lisa I Backus, Pamela S Belperio, Troy A Shahoumian, Timothy P Loomis, Larry A Mole
BACKGROUND: Predictors of SVR to all-oral hepatitis C virus (HCV) regimens can inform nuanced treatment decisions. We evaluated effectiveness and identified predictors of SVR for ledipasvir/sofosbuvir±ribavirin (LDV/SOF±RBV) and ombitasvir/paritaprevir/ritonavir+dasabuvir (OPrD)±RBV in patients treated in routine practice. METHODS: Observational, intent-to-treat cohort of 21,142 genotype 1 patients initiating 8 or 12 weeks of LDV/SOF±RBV or 12 weeks of OPrD±RBV at any Veterans Affairs facility...
December 9, 2016: Antiviral Therapy
https://www.readbyqxmd.com/read/27925609/a-comparison-of-virological-suppression-and-rebound-between-indigenous-and-non-indigenous-persons-initiating-combination-antiretroviral-therapy-in-a-multisite-cohort-of-individuals-living-with-hiv-in-canada
#17
Anita C Benoit, Jaime Younger, Kerrigan Beaver, Randy Jackson, Mona Loutfy, Renée Masching, Tony Nobis, Earl Nowgesic, Doe O'Brien-Teengs, Wanda Whitebird, Art Zoccole, Mark Hull, Denise Jaworsky, Anita Rachlis, Sean Rourke, Ann N Burchell, Curtis Cooper, Robert Hogg, Marina B Klein, Nima Machouf, Julio Montaner, Chris Tsoukas, Janet Raboud, Building Bridges
BACKGROUND: This study compared time to virologic suppression and rebound between Indigenous and non-Indigenous individuals living with HIV in Canada initiating combination antiretroviral therapy (cART). METHODS: Data were from the Canadian Observational Cohort collaboration; 8 studies of treatment-naïve persons with HIV initiating cART after 1/1/2000. Fine and Gray models were used to estimate the effect of ethnicity on 1) time to virologic suppression (two consecutive viral loads (VLs) <50 copies/mL at least three months apart) after adjusting for the competing risk of death and 2) time until virologic rebound (two consecutive VLs >200 copies/mL at least three months apart) following suppression...
December 7, 2016: Antiviral Therapy
https://www.readbyqxmd.com/read/27924780/activity-of-ergoferon-against-lethal-influenza-a-h3n2-virus-infection-in-mice
#18
Maria A Skarnovich, Alexandra G Emelyanova, Nataliia V Petrova, Alena A Borshcheva, Evgeniy A Gorbunov, Oleg Yu Mazurkov, Maksim O Skarnovich, Sergey A Tarasov, Larisa N Shishkina, Oleg I Epstein
BACKGROUND: The Influenza A virus accounts for serious annual viral upper respiratory tract infections. It is constantly able to modify its antigenic structure, thus evading host defence mechanisms. Moreover, currently available anti-influenza agents have a rather limited application, emphasising the further need for new effective treatments. One of them is Ergoferon, a drug, containing combined polyclonal antibodies - anti-interferon gamma, anti-CD4 receptor, and anti-histamine - in released-active form...
December 7, 2016: Antiviral Therapy
https://www.readbyqxmd.com/read/27924779/hepatic-safety-of-maraviroc-in-patients-with-hiv-1-and-hepatitis-c-and-or-b-virus-144-week-results-from-a-randomized-placebo-controlled-trial
#19
Juergen K Rockstroh, Frank Plonski, Meena Bansal, Gerd Fätkenheuer, Catherine B Small, David M Asmuth, Gilles Pialoux, Rebecca Zhang-Roper, Ronnie Wang, Juan A Pineda, Jayvant Heera
BACKGROUND: In the primary 48-week analysis of a hepatic safety trial in patients with HIV-1 co-infected with hepatitis B virus (HBV) and/or hepatitis C virus (HCV), maraviroc-containing treatment regimens were not associated with increased hepatotoxicity. METHODS: In this randomised, double-blind, placebo-controlled, multicentre study, patients received maraviroc twice daily (n=70) or placebo (n=67) with concomitant antiretroviral therapy for 144 weeks (clinicaltrials...
December 7, 2016: Antiviral Therapy
https://www.readbyqxmd.com/read/27922453/safety-and-efficacy-of-the-hiv-1-attachment-inhibitor-prodrug-fostemsavir-in-antiretroviral-experienced-subjects-week-48-analysis-of-ai438011-a-phase-iib-randomized-controlled-trial
#20
Melanie Thompson, Jacob P Lalezari, Richard Kaplan, Yvett Pinedo, Otto A Sussmann Pena, Pedro Cahn, David A Stock, Samit R Joshi, George J Hanna, Max Lataillade
BACKGROUND: Fostemsavir is a prodrug of temsavir, an attachment inhibitor that binds directly to HIV-1 gp120, blocking initial viral attachment and entry into host CD4 cells. Efficacy, safety, and dose-response data of fostemsavir in treatment-experienced, HIV-1-infected subjects, through Week 48, are reported. METHODS: AI438011 is an ongoing Phase IIb, randomized, active-controlled trial (NCT01384734). Subjects were randomized 1:1:1:1:1 into five arms: fostemsavir (400 mg twice daily [BID], 800 mg BID, 600 mg once daily [QD], or 1200 mg QD), and a reference arm (ritonavir-boosted atazanavir [ATV/r] 300/100 mg QD), each with a backbone of raltegravir 400 mg BID + tenofovir disoproxil fumarate 300 mg QD...
December 6, 2016: Antiviral Therapy
journal
journal
20043
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"